Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Results of implantation of aspheric intraocular lenses Optimed in preloaded system and Zeiss CT Asphina MV 40

Poster Details

First Author: M.Gizatullina RUSSIA

Co Author(s):    B. Aznabaev   T. Mukhamadeev   G. Idrisova              

Abstract Details

Purpose:

To evaluate the postoperative results after ultrasonic phacoemulsification and aspherical intraocular lenses (IOLs) 'Optimed' in preloaded system and 'Zeiss CT Asphina 409 MV' implantation.

Setting:

Bashkir State Medical University, CJSC 'Optimedservice' (Ufa, Russia).

Methods:

The results of ultrasonic phacoemulsification with aspheric IOIs implantation "Optimed" in preloaded system (the first group, 38 eyes) and "Zeiss CT Asphina the MV 409" (the second group, 36 eyes) were estimated. Before surgery and postoperatively spherical component of the refraction, deviation between the postoperative and planned clinical refraction, uncorrected visual acuity (UCVA) were estimated. Statistical analysis was performed using Microsoft Excel 2013, IBM SPSS Statistics ver. 21. Results were evaluated with Fisher’s exact and Mann-Whitney U tests.

Results:

One month after surgery, target refraction ± 0.25 D was achieved in 57.9% in the first group and 63.9% of cases in the second group (P˃0.05), target refraction ± 0.5 D was achieved in 84.2% and 97.2% of cases respectively (P˂0.05), target refraction ± 1.0 D was achieved in 100 % in both groups. Postoperative average UCVA was 0.63 ± 0.28 in the first group and 0.68 ± 0.32 in the second group (P˃0.05).

Conclusions:

Ultrasonic phacoemulsification with "Optimed" in preloaded system and "Zeiss CT Asphina the MV 409" IOL implantation allowed to obtain high refractive results. Our results are comparable to the standards the Royal College of Ophthalmologists (Cataract Surgery Guidelines has adopted a standard of 85% within ±1 D of target and 55% within ±0.5 D of target).

Financial Disclosure:

NONE

Back to Poster listing